Mediar Therapeutics
Clinical trials sponsored by Mediar Therapeutics, explained in plain language.
-
New antibody MTX-439 enters first human trial for diabetic kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called MTX-439, an antibody that blocks a protein linked to kidney scarring. It will be given to healthy volunteers and people with diabetic kidney disease to check for safety and how the body processes it. The study is small (88 participan…
Phase: PHASE1 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody drug aims to slow lung scarring in IPF
Disease control Recruiting nowThis phase 2 trial tests whether MTX-463, an antibody that blocks a protein linked to scarring, can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF). About 164 adults with IPF will receive either the drug or a placebo for 24 weeks. The main goal is to…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC